Wenzel M, Filzmayer M, Siech C, Le QC, et al. Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and >/= 10 bone metastases receiving apalutamide: a real-world cohort. BMC Cancer 2026 Mar 2. doi: 10.1186/s12885-026-15803.
PMID: 41772487